{"schema_version":"secwatch.filing_event.v1","accession":"0001082554-22-000006","form_type":"8-K","ticker":"UTHR","cik":"0001082554","company_name":"UNITED THERAPEUTICS Corp","filed_at":"2022-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.362764+00:00","generated_at":"2026-06-27T04:34:01.750468+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"United Therapeutics FY2021 revenue $1.69B (+14% YoY); Tyvaso DPI decision pushed to May 2022","bullets":["Full year 2021 revenue $1.69B, up 14% YoY; Q4 revenue $415M, up 8% YoY.","Net income $475.8M ($10.60 basic GAAP EPS); non-GAAP diluted EPS $15.26.","Tyvaso net sales $607.5M in 2021, up 26% YoY; Remodulin down 1% to $513.7M.","Tyvaso DPI NDA extended to May 2022 after FDA requested info on pulmonary safety related to Citizen Petition.","Patient count reached all-time high; target of 6,000 Tyvaso patients by end of 2022 reaffirmed."],"urls":{"canonical":"https://secwatch.observer/filing/0001082554-22-000006","json":"https://secwatch.observer/filing/0001082554-22-000006.json","markdown":"https://secwatch.observer/filing/0001082554-22-000006.md","text":"https://secwatch.observer/filing/0001082554-22-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1082554/000108255422000006/0001082554-22-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1082554/000108255422000006/uthr-20220224.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T04:34:01.750468+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}